Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Feb 12, 2009


Gary Gilliland has taken on two posts at Merck, including vice president of Merck Research Laboratories and franchise head of oncology.

Gilliland is a Harvard Medical School professor and a Howard Hughes Medical Institute investigator. He is also director for the Leukemia Program at the Dana Farber/Harvard Medical Cancer Center and director of the Cancer Stem Cell Program at the Harvard Stem Cell Institute.

He will replace Stephen Friend, who plans to leave the company to pursue an effort to build open access integrative bionetworks, or complex databases, around the world in order to accelerate disease studies.